{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-107952","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.550866+00:00","generated_at":"2026-06-23T04:06:43.732848+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avenue Therapeutics closes $12M offering, net $10.4M; uses proceeds to repurchase InvaGen shares","bullets":["Closed underwritten offering of 3,636,365 units at $3.30/unit; net proceeds ~$10.4M.","Proceeds to repurchase all shares held by InvaGen Pharmaceuticals; remainder for working capital.","Believes it now complies with Nasdaq equity requirement (min $2.5M) and bid price >$1.00 for 13 days.","Underwriter Aegis Capital Corp. also purchased 545,454 additional warrants via over-allotment.","Company awaiting formal Nasdaq compliance determination from Panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-107952","json":"https://secwatch.observer/filing/0001104659-22-107952.json","markdown":"https://secwatch.observer/filing/0001104659-22-107952.md","text":"https://secwatch.observer/filing/0001104659-22-107952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922107952/0001104659-22-107952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922107952/tm2228055d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:06:43.732848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}